索他洛尔与普罗帕酮平行对照治疗阵发性心房颤动

目的：评价索他洛尔与普罗帕酮平行对照治疗阵发性心房颤动的临床疗效和安全性。方法：本研究为随机、平行对照研究。138例阵发性心房颤动患者经2周洗脱期后,随机分为索他洛尔组（每日2次,剂量从40 mg/d开始,根据具体情况,适量渐增,最大剂量320 mg/d。n=68）和普罗帕酮组（每日3次,剂量从450 mg/d开始,根据具体情况,适量渐增,最大剂量不超过800 mg/d。n=70）,治疗12周末评价两组疗效。结果：随机、平行对照治疗12周末的总有效率,索他洛尔组为72.06%;普罗帕酮组为62.86%。两组组间比较均有统计学意义（P〈0.01）。索他洛尔组与普罗帕酮组的不良反应发生率分别为8.82%和18.57%（P〈0.01）。结论：索他洛尔治疗阵发性心房颤动患者的疗效明显优于普罗帕酮,且有良好的安全性。

Comparison of Sotalol Therapy with Propafenone Therapy in the Patients with Paroxysmal Atrial Fibrillation

Objective：To evaluate the efficacy and safety of sotalol therapy,compared with propafenone therapy in patients with paroxysmal atrial fibrillation.Methods：In a multicentre,randomized,parallel controlled trial,138 cases of paroxysmal atrial fibrillation after 2 weeks washout period,were randomly divided into the sotalol group（twice daily doses from 80 mg / day,depending on the circumstances,the amount increasing,the maximum dose of 320 mg/day.n=68） and propafenone group（three times a day,the dose from 450 mg/day,depending on the circumstances,the amount increasing,the maximum dose does not exceed 800 mg/day.n=70）,The primary endpoint was to evaluate the total successful response rate to treatment at the end of 12 week treatment.Results：The randomized,parallel-group treatment of the total successful response rate to treatment of 12 weeks were 72.06% in the sotalol therapy group and 62.86% in in the propafenone therapy group,respectively.There were statistically significant difference between the sotalol therapy group and the propafenone therapy groups（P0.01）.Adverse events rates were 8.82% in the sotalol therapy group and 18.57% in the propafenone group（P0.01）.Conclusion：Sotalol in the treatment of paroxysmal atrial fibrillation in patients with curative effect is obvious better than propafenone,and has the advantages of good safety